Login to Your Account



Investor-Focused Tax Strategy

Resverlogix Spins Out Platform To Make Tidy M&A Package

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, April 15, 2013

Resverlogix Corp. announced last week that it's spinning out its epigenetics platform into RVX Therapeutics Inc., leaving its ApoA-I stimulating drug candidate, RVX-208, with the parent company.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription